Holen Sie sich die Stockscreener-App
8.63
11.03%
-1.07
Handel nachbörslich:
8.41
-0.22
-2.55%
Schlusskurs vom Vortag:
$9.70
Offen:
$8.685
24-Stunden-Volumen:
8.45M
Relative Volume:
1.45
Marktkapitalisierung:
$724.45M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-313.94M
KGV:
-2.4615
EPS:
-3.506
Netto-Cashflow:
$-284.57M
1W Leistung:
-17.89%
1M Leistung:
-25.80%
6M Leistung:
+14.61%
1J Leistung:
+173.97%
1-Tages-Spanne:
$7.37
$9.15
1-Wochen-Bereich:
$7.37
$11.23
52-Wochen-Spanne:
$1.50
$12.50
Replimune Group Inc Stock (REPL) Company Profile
Firmenname
Replimune Group Inc
Sektor
Branche
Telefon
(781) 222-9600
Adresse
500 UNICORN PARK, WOBURN, MA
Compare REPL vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
8.63 | 814.27M | 0 | -313.94M | -284.57M | -3.506 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-13 | Herabstufung | BMO Capital Markets | Market Perform → Underperform |
| 2026-04-13 | Herabstufung | H.C. Wainwright | Buy → Sell |
| 2026-04-13 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2026-04-13 | Herabstufung | Jefferies | Buy → Hold |
| 2026-04-13 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2026-04-13 | Herabstufung | Wedbush | Outperform → Neutral |
| 2026-04-10 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-11-03 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
| 2025-10-27 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-20 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2025-10-20 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-10-20 | Hochstufung | Wedbush | Neutral → Outperform |
| 2025-09-19 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-07-30 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-23 | Herabstufung | BMO Capital Markets | Outperform → Underperform |
| 2025-07-23 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-07-23 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-07-22 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-07-22 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-07-22 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-07-22 | Herabstufung | Wedbush | Outperform → Neutral |
| 2025-06-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-28 | Eingeleitet | ROTH MKM | Buy |
| 2023-04-17 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2020-11-17 | Eingeleitet | BTIG Research | Buy |
| 2020-11-02 | Eingeleitet | Jefferies | Buy |
| 2020-10-15 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | Eingeleitet | Barclays | Overweight |
| 2019-09-04 | Eingeleitet | ROTH Capital | Buy |
| 2019-07-23 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-07-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-07-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-04-25 | Eingeleitet | Wedbush | Outperform |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-08-14 | Eingeleitet | JP Morgan | Overweight |
| 2018-08-14 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Replimune Group Inc Aktie (REPL) Neueste Nachrichten
Replimune Group Inc (REPL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Replimune Group Market Sentiment - Benzinga España
REPL|Replimune Group Inc|Price:9.700|Chg%:-0.760 - TradingKey
Replimune Group Inc (REPL) Institutional Confidence - TradingKey
Replimune Group Inc (REPL) Valuation: PE, PB & Fair Value Analysis - TradingKey
TradingKey - TradingKey
Replimune Group Inc (REPL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
REPL Vs IOVA: FDA Decision Day Could Test Biotech Bulls’ Conviction On These Melanoma Plays - Stocktwits
REPL Stock On Track For Worst Drop In Nearly 7 Months Ahead Of FDA Decision On Skin Cancer Drug - Stocktwits
REPL|Replimune Group Inc|Price:9.695|Chg%:-0.765 - TradingKey
Replimune Group Inc (REPL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Replimune Group (REPL) Q3 2026 Earnings ReportResults, Call & Slides - TipRanks
Lost Money on Replimune Group, Inc. (REPL)? Contact Levi & Korsin - The National Law Review
Replimune Group, Inc. Revenue Breakdown – NASDAQ:REPL - TradingView
Replimune Group Inc (REPL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Replimune stock trades lower after cash burn and clinical updates shape outlook - Ad-hoc-news.de
Replimune's RP1 Drug Probably Works, But It's Not A Buy Yet (NASDAQ:REPL) - Seeking Alpha
REPL Stock Lost 19% Of Its Value Today – Why Did The FDA Refuse Approval For Its Experimental Melanoma Drug? - Stocktwits
Replimune stock gains after updated RP1 data and cash runway outlook - AD HOC NEWS
ETFs Investing in Replimune Group, Inc. Stocks - TradingView
REPL Stock On Track To Hit All-Time Lows – Here’s Why This Analyst Slashed Price Target By 85% - Stocktwits
BMO Capital downgrades Replimune Group (REPL) - MSN
Liquidity Mapping Around (REPL) Price Events - Stock Traders Daily
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Replimune Group, Inc. (REPL) - GlobeNewswire
Form PRE 14A REPLIMUNE GROUP For: 13 July By Investing.com - Investing.com Nigeria
Price to earnings forward of Replimune Group, Inc. – MUN:7R8 - TradingView
Replimune Group (NASDAQ: REPL) seeks approval to double authorized stock - Stock Titan
Replimune Group (REPL) Q4 2026 earnings summary - Quartr
Replimune soars after FDA reconsiders denial of cancer drug - MSN
symbol__ Stock Quote Price and Forecast - CNN
Replimune Group Inc. (REPL) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
9 Health Care Stocks With Whale Alerts In Today’s Session - Benzinga
REPL Stock Rallies In Anticipation Of FDA Decision On Skin Cancer Drug - Stocktwits
Replimune Group stock and its cancer immunotherapy pipeline - Ad-hoc-news.de
3 Biotech Stocks to Watch Before Wall Street Catches On - TradingView
Replimune Group Inc. (REPL) Holds Gains Near Resistance as Support HoldsDelta Hedging - DonanımHaber
The week in pharma: action, reaction and insight – week to July 3, 2026 - The Pharma Letter
Replimune says FDA rejected its lead drug for skin cancer - MSN
Analysts Offer Insights on Healthcare Companies: Replimune Group (REPL) and Roche Holding AG (OtherRHHVF) - The Globe and Mail
REPL Maintains Neutral Rating by Wedbush -- Price Target Raised to $9.00 - GuruFocus
Replimune: Stock Buoyant On Third Try At RP1 ApprovalFDA AdCom May Be Crucial (REPL) - Seeking Alpha
Finanzdaten der Replimune Group Inc-Aktie (REPL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):